Targeted Protein Degradation Enabling Technologies Industry Report by 2030 | Roots Analysis

Targeted Protein Degradation
Targeted Protein Degradation

Targeted protein degradation has emerged as a revolutionary pharmacological concept that presents both viable and versatile drug development opportunities and is anticipated to introduce a new paradigm in modern healthcare.

Targeted Protein Degradation Enabling Technologies


Roots Analysis has announced the addition of the “Targeted Protein Degradation Market, 2021-2030” report to its list of offerings.

Small-molecule-induced protein degradation has been demonstrated to possess the potential to drug a broader range of proteinaceous biological targets. It involves the selective recruitment of the body’s inherent protein degradation pathways, to eliminate disease-causing / associated proteins, using bifunctional small molecule drugs. Presently, the most popular and promising class of interventions in this field of research is proteolysis targeting chimeras (PROTACs); these can simultaneously bind a target protein and an E3-ubiquitin ligase, and thereby, facilitate the selective ubiquitination and eventual proteasome-mediated degradation of the target protein. The most interesting feature of this mechanism of drug action is the fact that PROTACs and other targeted protein degraders can eliminate protein targets regardless of their function.

Access Full Report:

Key Market Insights

Presently, more than 150 targeted protein degradation-based therapeutics are currently under development

Around 75% of the aforementioned candidates are in the preclinical and discovery stages, followed by those that are being evaluated in clinical trials (25%). These degrader molecules are PROTAC (26), followed by DUB inhibitors (15%), protein homeostatic modulators (14%), and SERDs/SARDs (13%).

Over 40 targeted protein degradation enabling technologies are presently available / under development

Of these, the PROTAC® platform is presently considered the most popular, with 15 product candidates, developed using the same technology, under investigation. On the other hand, there are presently 10 technologies that are designed to design/develop DUB inhibitors.

Around 80 companies claim to be engaged in the development of targeted protein degradation-based therapeutics

Post-2010, there has been a notable surge in the number of companies developing targeted protein degraders. The majority of the firms engaged in this field (57%) are based in North America, followed by Europe (27%) and the Asia Pacific (16%).

Over 80 registered clinical trials are presently assessing targeted protein degradation-based therapeutics, worldwide

It is worth mentioning that most of the clinical research in this direction is being conducted in Europe (60%), followed by North America and the Asia Pacific. However, more than 40% of the total number of patients enrolled in such trials are in North America.

Over 770 grants have been awarded to support research on targeted protein degradation-based therapeutics, since 2016

An estimated total of USD 345 million in grants has been awarded to various organizations working in this domain, during the period between January 2016 to December 2020. Almost 40% of the total number of grants were provided by the National Cancer Institute.

More than 14,500 patents have been filed/granted related to targeted protein degradation enabling technologies, since 2018

Around 50% of these intellectual property documents were filed/granted in the US; other key regions with significant intellectual capital include Australia, China, Japan, Canada and Korea. Leading nonindustry players (in terms of the size of intellectual property portfolio) include the University of California, Massachusetts Institute of Technology, Broad Institute, Harvard College, and Dana Farber Cancer Institute.

Partnership activity within this domain has grown significantly between 2014 and 2021

The maximum number of partnerships for targeted protein degradation-based therapeutics were signed in 2018. R&D agreements (25%) and research agreements (23%) emerged as the most popular types of partnership models adopted so far, by stakeholders in this industry.

Over USD 5 billion has been invested by both private and public investors, since 2014

Companies involved in the development of targeted protein degradation-based therapeutics have raised around USD 2.3 billion through venture capital financing, which represents 43% of the total capital raised in the given time period. Overall, more than 180 investors have actively financed projects/initiatives in this domain.

Presently, the market is driven by revenues from therapy development enabling technologies; it is anticipated to grow at a CAGR of around 27%, till 2030

Over 50% of the technology licensing-related opportunity is associated with platforms intended for drugs targeting oncological disorders; this trend is unlikely to change in the foreseen future. North America is expected to capture over 55% of the market share by 2030

Request for Customization:

Key Questions Answered

  • Who are the leading industry and non-industry players in this market?
  • What are the key therapeutic areas for which targeted protein degraders are being/have been developed?
  • Which geographies are more active in conducting clinical trials on targeted protein degraders?
  • What kind of partnership models are commonly adopted by industry stakeholders?
  • Which are the leading administering institute centers supporting research in this domain?
  • What is the trend of capital investments in the targeted protein degradation market?
  • How has the intellectual property landscape in this market evolved over the years?
  • How is the current and future market opportunity likely to be distributed across key market segments?

The USD 3.3 billion (by 2030) financial opportunity within the targeted protein degradation enabling technologies market has been analyzed across the following segments:

Type of Payment

  • Upfront Payment
  • Milestone Payment

Types of Protein Degraders

  • Degronimids
  • SARDs / SERDs
  • Specific BET and DUB Inhibitors
  • Other Inhibitors

Therapeutic Areas

  • Oncological Disorders
  • Neurological Disorders
  • Others

Route of Administration

  • Oral
  • Intravenous
  • Others

Key Geographical Regions

  • North America
  • Europe
  • Asia-Pacific

The research includes detailed profiles of key players (listed below); each profile features an overview of the company, its financial information (if available), brief descriptions of its proprietary drug(s) and an informed future outlook.

  • Arvinas
  • AstraZeneca
  • BioTheryX
  • C4 Therapeutics
  • Captor Therapeutics
  • Celgene
  • Genentech
  • Innova Pharmaceuticals
  • Kangpu Biopharmaceuticals
  • Kymera Therapeutics
  • Mission Therapeutics
  • Program
  • Radius Health
  • Sanofi Genzyme
  • Zenopharm

Request for PDF Sample:

About Roots Analysis

Roots Analysis is one of the fastest-growing market research companies, sharing fresh and independent perspectives in the biopharmaceutical industry. The in-depth research, analysis, and insights are driven by an experienced leadership team that has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at

Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415



Also, have a Look at Our Upcoming Research Reports

Soft Tissue Sarcoma: Pipeline Review, Developer Landscape, and Competitive Insights, 2021-2031

Cloud-based Solutions for Drug Discovery, Development and Manufacturing Market Trends, and Global Forecasts, 2021-2030

Spinal Muscular Atrophy Market, 2021-2031

Dravet Syndrome Market, 2021-2031

Hypertrophic Cardiomyopathy Market 2021-2031


  1. Betting is a popular pastime for most Americans. Countless Americans enjoy gaming on the web or on the race tracks. Americans enjoy betting because they like winning and they like the struggle of betting. This is an enjoyable outlet of energy and for many Americans it can replace unhealthy lifestyles and add excitement into their own lives.

    Thus why do gamblers tend to have a long term advantage over other gamblers? Many gamblers have been known to drift away from a match with more income than they started off with. Some players may have bet that a touch too much rather than have it work to their advantage. What could a player do to have a long term advantage and earn more money than they’d ever have gambled together if they had not found a means to develop into better player?

    Everything boils down to skill and learning more strategies. Most gamblers will probably be familiarized with a number of the very popular advantages which gamblers use to win. There are a number of distinct factors that may influence a person’s ability to observe such advantages and become a long-term winner. If a person has plenty of experience in a particular match plus they truly are proficient in playing with a particular game then they’ll have a very noticeable advantage in comparison with some one who does not have experience in that match.


Please enter your comment!
Please enter your name here